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Gelidium amansii (GA) is an edible red algae that is distributed mainly in northeastern
Taiwan. This study was designed to investigate the effects of GA on plasma glucose, lipids,
and adipocytokines in rats with streptozotocin-nicotinamide-induced diabetes. Rats were
divided into four groups: (1) rats without diabetes fed a high-fat diet (control group); (2) rats
with diabetes fed a high-fat diet; (3) rats with diabetes fed a high-fat diet with thiazolidi-
nedione in the diet; and (4) rats with diabetes fed a high-fat diet and GA. The experimental
diet and drinking water were available ad libitum for 11 weeks. After the 11-week feeding
study, plasma glucose, triglyceride, and cholesterol concentrations were lower in rats with
diabetes fed the GA diet than in animals with diabetes fed the control diet. In addition,
cholesterol and triglyceride excretion were significantly higher in rats with diabetes fed the
GA diet. Moreover, GA feeding induced lipolysis in both paraepididymal and perirenal
adipose tissues. Adipose tissue (paraepididymal and perirenal) weight and triglyceride
contents were lower after GA treatment. Plasma adipocytokines including tumor necrosis
factor-alpha, interleukin-6, and plasminogen activator inhibitor-1 were reduced by GA
feeding in rats with diabetes. The results of the current study suggest that GA feeding may
regulate plasma glucose and lipid levels and prevent adipose tissue accumulation in rats
with diabetes.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.
 
Open access under CC BY-NC-ND license.1. Introduction
Diabetes is a metabolic disease in which insulin secretion is
lacking or insulin is not properly utilized. Patients with type 2Science, National Taiwa
(M.-T. Chiang).
ministration, Taiwan. Publdiabetes have a higher risk of atherosclerosis, cerebrovascular
disease, hypertension, hyperlipidemia, and other complica-
tions [1]. Clinical observations suggest that type 2 diabetes and
obesity are closely linked [2e5]. In addition, plasma adipocy-
tokines such as tumor necrosis factor-alpha (TNF-a),n Ocean University, 2 Pei-Ning Road, Keelung, Taiwan.
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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(PAI-1) are related to inflammation in pathological condi-
tions such as diabetes and obesity [6].
Recent evidence suggests that algae have many beneficial
effects on reducing plasma lipids, glucose, and obesity. For
example, wakame, an edible brown algae, has been reported
to suppress white adipose tissue weight gain and plasma
glucose levels in obese mice fed a high-fat diet [7]. In addition,
kombu, a type of brown algae, was shown to lower blood lipids
and improve antioxidant enzyme activities, which may
reduce risk factors for cardiovascular disease in patients with
type 2 diabetes [8]. In addition, a survey from the Korean Na-
tional Health and Nutrition Examination Survey in 2005 sug-
gested that dietary algae consumption may decrease the risk
of type 2 diabetes mellitus [9].
Gelidium amansii (GA) is an edible red algae that is widely
distributed in northeastern Taiwan. Its agar product (1,3-
linked b-D-galactopyranose and 1,4-linked 3,6-anhydro-a-L-
galactopyranose units) [10] is prepared by boiling, filtering,
cooling, and then forming a gel [11]. To date, agar adminis-
tration to animals or cells has been shown to prolong blood
clotting time [12] and have antitumor [11,13] and antioxidant
[14] effects. Furthermore, GA has been reported to have a
hypoglycemic effect in rats [15] and patients with diabetes
[16]. However, the exactmechanisms of this effect are not well
understood. In addition, there is little information about the
effect of GA on obesity.
Rats with streptozotocin-nicotinamide-induced type 2
diabetes can exhibit hyperglycemia, glucose intolerance, and
obesitywhen fed a high-fat diet [17,18]. This animalmodel has
been used in our previous studies for evaluating functional
foods on reducing diabetes and obesity [19e21]. In this study,
we used this animal model to investigate the effects of GA
feeding on plasma glucose, lipids, adipocytokines, and adi-
pose tissue weight in rats with diabetes.2. Materials and methods
2.1. Gelidium amansii
GA Lamouroux (dry) was purchased in Keelung, the northeast
corner of Taiwan. GA was minced using a grinder and then
stored at 4C until used. General compositions, including
moisture (7.1%), ash (4.7%), crude fat (0.7%), crude protein
(17%), water-soluble dietary fiber (45.9%), and water-insoluble
dietary fiber (15.4%) of GAwere determined using themethods
of the Association of Official Agricultural Chemists (AOAC)
[22,23].
2.2. Animals and treatments
Six-week-oldmale Sprague-Dawley rats were purchased from
BioLASCO Taiwan Co., Ltd., (Taipei, Taiwan). Rats were
housed in individual stainless steel cages in a room kept at
23 ± 1C and 40e60% relative humidity with a 12-hour light-
edark cycle. Rats were fed a standard laboratory diet (Rodent
Laboratory Chow; Ralston Purina, St. Louis, MO, USA) for 1
week and were then divided into four groups of eight rats
each. The four groups were as follows: rats without diabetesfed a high-fat diet (control group), rats with diabetes fed a
high-fat diet (DM group), rats with diabetes fed a high-fat diet
with thiazolidinedione in the diet (TZD group), and rats with
diabetes fed a high-fat diet and GA (GA group). The composi-
tion of the experimental diet was 20% protein, 57.1% carbo-
hydrates, 12% fat (10% lardþ 2% soybean oil), vitaminmixture
(1%), mineral mixture (4%), cholesterol (0.5%), cholic acid
(0.2%), choline chloride (0.2%), and corn starch (57.1%).
Vitamin and mineral mixtures (AIN 76) were purchased from
ICN Biochemicals (Costa Mesa, CA, USA). Either 5% GA or
microcrystalline cellulose (control fiber) was added as a di-
etary fiber source. The TZD group consumed the same diet as
the control and DM groups except that the diet contained
0.043% TZD (Torrent Pharmaceuticals Ltd., Ahmedabad,
India), which was approximately equivalent to 0.8 mg/kg body
weight for the daily dose. TZD is a class of medication used in
the treatment of type 2 diabetes mellitus.
Diabetes was induced in the rats by the intraperitoneal
injection of nicotinamide (230 mg/kg body weight in water;
Sigma, St. Louis, MO, USA) 15 minutes before the intraperito-
neal injection of STZ (65 mg/kg body weight in 0.05M citrate
buffer; pH 4.5; Sigma). After 1 week, an oral glucose tolerance
test (OGTT) was conducted to check the status of glucose
intolerance after glucose challenge (2 g/kg body weight).
During the experiment, an OGTT was conducted at the 4th
week and 8th week. Blood was collected from the tail vein at
0 minutes, 30 minutes, 60 minutes, 120 minutes, and 180
minutes.
The rats were fed the experimental diets for 11weeks. Food
and drinking water were available ad libitum. Body weight was
measured every week and feces were collected during the
final 3 days of the experiment. The feces samples were then
dried and weighed. This study was approved by the Animal
HouseManagement Committee of the National Taiwan Ocean
University. The animals were maintained in accordance with
the guidelines for the care and use of laboratory animals as
issued by the Animal Center of the National Science Council.
2.3. Collection of blood and tissue samples
At the end of the experiment, rats were fasted overnight and
then killed by exsanguination via the abdominal aorta while
under diethyl ether anesthesia. Heparin was used as the
anticoagulant. Plasma was collected by centrifugation at
1750g for 20minutes (4C) fromwhole blood. Liver and adipose
tissues (perirenal and paraepididymal) were excised from
each rat and weighed. All tissue samples were immediately
frozen and were stored at 80C until further analysis.
2.4. Determination of plasma glucose, insulin, leptin,
adiponectin, TNF-a, IL-6, PAI-1, aspartate
aminotransferase, alanine aminotransferase, and insulin
resistance
Plasma glucose was determined using an enzymatic kit (Audit
Diagnostics, Cork, Ireland). Plasma insulin concentrations
were determined using a rat insulin enzyme-linked immu-
nosorbent assay (ELISA) kit (Mercodia AB, Uppsala, Sweden).
Plasma leptin and adiponectin concentrations weremeasured
using a rat leptin ELISA kit (Assay Designs, Inc., USA) and rat
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California, USA), respectively. Plasma TNF-a concentration
was determined using a rat TNF-a ELISA kit (R&D Systems,
Inc., Minneapolis, USA). The plasma IL-6 and PAI-1 levels were
determined using a rat IL-6 immunoassay ELISA kit (R&D
Systems, Inc.) and Zymutest rat PAI-1 ELISA kit (Hyphen Bio-
Med, Neuville Sur Oise, France), respectively. The homeostasis
model assessment equation for insulin resistance (HOMA-IR)
was expressed as an index of insulin resistance: fasting
glucose concentration (mmol/L)  fasting insulin concentra-
tion (mU/L)/22.5. Plasma aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) were determined using
an enzymatic kit (Randox Ltd, Antrim, UK) and ALT enzymatic
kit (Randox Ltd), respectively.
2.5. Determination of plasma lipids, liver lipids, fecal
lipids, and adipose tissue lipid concentrations
Plasma total cholesterol and triglyceride concentrations were
determined using a cholesterol enzymatic kit (Audit Di-
agnostics) and triglyceride enzymatic kit (Audit Diagnostics),
respectively. The concentration of lipoprotein in plasma was
determined using ultracentrifugation (194,000g for 3 hours at
10C) [24]. The total cholesterol levels of the lipoprotein frac-
tion were measured using a cholesterol enzymatic kit (Audit
Diagnostics).
Liver, adipose tissue, and fecal lipids were extracted with
chloroform/methanol solution (v/v, 2:1) according to the
method of Folch et al [25]. Triglyceride and cholesterol were
determined using the method of Carlson and Goldfarb [26].
2.6. Determination of lipolysis rate and lipoprotein
lipase activity
The lipolysis rate was analyzed according to the procedure of
Morimoto et al [27]. Adipose tissue has a very low level of
glycerol kinase, and glycerol release is a valid index of the
lipolysis rate and thus of hormone-sensitive lipase activity.
Adipose pads (paraepididymal or perirenal) were rinsed in a
0.85% NaCl solution, patted dry, and weighed, and then 0.2 g
was added to 1.0 mL of prewarmed TES [N-tris (hydrox-
ymethyl) methyl-2-aminoethanesulfonic acid] buffer (con-
taining 1mM isoproterenol) and incubated at 37C for 1 hour.
After incubation at 70C for 10 minutes, the reaction mixtureTable 1 e Body weights and tissue weights of diabetic rats fed
Con
Initial body weight (g) 417.6 ± 24.8
Final body weight (g) 613.9 ± 53.1
Liver weight (g) 31.8 ± 4.0
Relative liver weight (g/100 g BW) 5.2 ± 0.5*
Perirenal fat (g) 21.4 ± 6.5
Paraepididymal fat (g) 13.1 ± 2.9
Relative adipose tissue weight (g/100 g BW) 5.6 ± 1.3
Relative adipose tissue weight: (perirenal fat þ paraepididymal fat)/final
Data are presented as mean ± SD values (n ¼ 7e8).
*p < 0.05 compared with the DM group.
BW¼ bodyweight; Con¼ rats without diabetes fed a high-fat diet; DM¼ ra
fat diet and Gelidium amansii; SD ¼ standard deviation; TZD ¼ rats with dwas centrifuged at 100g at room temperature for 30 seconds.
The resulting supernatant was used to determine the glycerol
content (Randox Diagnostic, Crumlin, Northern Ireland, UK).
Adipose tissue heparin-triggered lipoprotein lipase (LPL) ac-
tivity was measured according to the method of Murase et al
[28]. A specimen of adipose tissue weighing 0.1 g was minced
into small pieces and placed in Krebs-Ringer Bicarbonate
(KRB) buffer (pH 7.4) in the presence of heparin for 60 minutes
at 37C. LPL activity was then assayed using p-nitrophenyl
butyrate as the probe substrate, and the rate of p-nitrophenol
released from the incubation medium was measured.
2.7. Statistical analysis
Results are given as mean ± standard deviation values. Sta-
tistical differences among groups were calculated using
analysis of variance (ANOVA; SAS Institute, Cary, NC, USA),
and groupmeans were considered to be significantly different
at p < 0.05 as determined by the Duncan multiple range test.3. Results
3.1. Body and organ weights
The body, liver, and adipose tissue weights in the four groups
of rats after 11 weeks of the experimental diets are shown in
Table 1. Body weight did not differ significantly among the
groups. Liver weight, however, was significantly lower in the
rats with diabetes fed the thiazolidinedione (TZD group) and
GA diet (GA group) than in the rats with diabetes fed the cel-
lulose diet (DM group). The relative liver weight was reduced
in both the TZD and GA groups compared with the DM group.
Paraepididymal, perirenal, and relative adipose tissueweights
were significantly lower in the GA group than in the DM group.
3.2. Plasma glucose and HOMA-IR
As shown in Table 2, plasma glucose concentrations at 30
minutes, 60 minutes, and 120 minutes were lower (p < 0.05) in
the GA group than in the DM group after an oral glucose
challenge (2 g/kg body weight). At 4 weeks, glucose concen-
trations were also lower (p < 0.05) at 30 and 60 minutes in the
TZD group than in the DM group. At 8 weeks, glucosedifferent experimental diets for 11 weeks.
DM TZD GA
403.1 ± 30.8 406.4 ± 22.7 403.3 ± 29.6
607.9 ± 52.0 612.8 ± 44.9 567.6 ± 60.0
36.8 ± 5.2 31.0 ± 4.4* 27.7 ± 5.2*
6.0 ± 0.5 5.1 ± 0.5* 4.8 ± 0.4*
23.0 ± 4.9 20.6 ± 5.2 16.5 ± 5.1*
13.9 ± 2.3 11.9 ± 3.3 10.3 ± 2.9*
6.1 ± 1.1 5.3 ± 1.1 4.6 ± 1.0*
BW  100.
ts with diabetes fed a high-fat diet; GA¼ rats with diabetes fed a high-
iabetes fed a high-fat diet with thiazolidinedione in the diet.
Table 2e Plasma glucose concentrations after an oral glucose tolerance test in ratswith diabetes fed different experimental
diets for 11 weeks.
Con DM TZD GA
4 weeks glucose (mg/dL)
0 min 171.7 ± 19.1* 208.3 ± 23.7 231.7 ± 26.3 191.6 ± 20.3
30 min 207.1 ± 42.1* 348.2 ± 57.6 286.2 ± 52.9* 262.4 ± 45.1*
60 min 197.0 ± 21.7* 374.6 ± 41.9 311.3 ± 64.4* 291.8 ± 46.8*
120 min 181.6 ± 18.7* 284.4 ± 28.0 241.9 ± 50.1 244.8 ± 32.1*
180 min 178.0 ± 18.0* 231.1 ± 32.9 238.9 ± 32.5 248.6 ± 36.8
8 weeks glucose (mg/dL)
0 min 161.2 ± 19.9 179.6 ± 25.9 175.9 ± 18.6 170.2 ± 8.6
30 min 195.6 ± 21.5* 249.0 ± 11.7 231.8 ± 51.2 239.6 ± 43.8
60 min 183.2 ± 21.0* 247.4 ± 45.8 198.0 ± 41.5* 231.6 ± 56.3
120 min 161.2 ± 22.6* 234.9 ± 17.8 187.1 ± 38.5* 203.6 ± 31.3*
180 min 161.5 ± 19.9* 241.0 ± 38.7 195.1 ± 19.6* 217.6 ± 42.4
Data are presented as mean ± SD values (n ¼ 7e8).
*p < 0.05 compared with the DM group.
Con ¼ rats without diabetes fed a high-fat diet; DM ¼ rats with diabetes fed a high-fat diet; GA ¼ rats with diabetes fed a high-fat diet and
Gelidium amansii; SD ¼ standard deviation; TZD, rats with diabetes fed a high-fat diet with thiazolidinedione in the diet.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 3 ( 2 0 1 5 ) 7 5 8e7 6 5 761concentrations were lower (p < 0.05) at 60 minutes, 120 mi-
nutes, and 180 minutes in the TZD group than in the DM
group. Also at 8 weeks, glucose concentrations were signifi-
cantly lower (p < 0.05) in the GA group than in the DM group at
120 minutes only.
Although the plasma glucose concentration and HOMA-IR
value were lower in the GA group than in the DM group after
11 weeks of the feeding study, the differences in insulin was
not significant (Table 3).3.3. Plasma adipocytokine levels
The results of plasma adipocytokine measurements are
shown in Table 3. Plasma PAI-1 concentrations were higher
(p < 0.05) in the rats with diabetes than in the control rats
without diabetes. However, PAI-1 elevations were reduced
(p < 0.05) by GA treatment. In addition, plasma leptin, IL-6 and
TNF-a levels were lower in the GA group than in the DM group.Table 3 e Plasma concentrations of glucose, insulin resistance
PAI-1, AST,and ALT in rats with diabetes fed different experim
Con
Glucose (mg/dL) 207.7 ± 23.4* 257
Insulin (mg/L) 0.50 ± 0.24 0.
HOMA-IRa 6.3 ± 2.8 10
Leptin (ng/mL) 4.8 ± 2.7 6
Adiponectin (mg/mL) 11.6 ± 3.6 9
TNF-a (pg/mL) 43.6 ± 20.9 46
IL-6 (pg/mL) 26.8 ± 11.5 33
PAI-1 (ng/mL) 2.4 ± 0.8* 5
AST (U/L) 69.5 ± 19.1 68
ALT (U/L) 27.6 ± 7.8 31
Data are presented as mean ± SD values (n ¼ 7e8).
ALT ¼ alanine aminotransferase; AST ¼ aspartate transaminase; Con ¼ ra
high-fat diet; GA ¼ rats with diabetes fed a high-fat diet and Gelidium am
TNF-a ¼ tumor necrosis factor-alpha; TZD ¼ rats with diabetes fed a high
*p < 0.05 compared with the DM group.
a Homeostasis model assessment (HOMA) equation for insulin resistance
insulin concentration (mU/L)/22.5.The plasma adiponectin concentration was higher in the TZD
and GA groups than in the DM group. In addition, rats fed a
diet containing GA or TZD had no effect on plasma AST and
ALT activities, indicating GA or TZD caused no hepatotoxicity
(Table 3).3.4. Plasma, liver, and fecal lipid contents
The results of plasma lipid measurements are shown in
Table 4. The plasma total cholesterol and triglyceride levels
were reduced (p < 0.05) by TZD or GA treatment. In addition,
rats with diabetes fed the TZD and GA diet had lower (p < 0.05)
plasma concentrations of LDL-C (low-density lipoprotein
cholesterol) þ VLDL-C (very-low-density lipoprotein choles-
terol) than in the animals with diabetes fed the cellulose diet
(DM group).
The results of liver lipid measurements are also shown in
Table 4. After 11 weeks of treatment, hepatic total cholesterolindex (HOMA-IR), insulin, leptin, adiponectin, TNF-a, IL-6,
ental diets for 11 weeks.
DM TZD GA
.6 ± 14.8 229.4 ± 34.5 221.2 ± 21.7*
68 ± 0.31 0.40 ± 0.13 0.42 ± 0.15
.8 ± 5.1 5.6 ± 2.1* 5.8 ± 2.2*
.7 ± 2.7 6.8 ± 2.1 3.9 ± 2.0*
.0 ± 1.2 12.9 ± 2.6* 11.2 ± 2.0*
.8 ± 25.7 33.5 ± 22.1 24.0 ± 9.9*
.5 ± 7.4 25.5 ± 11.2 19.2 ± 4.6*
.1 ± 1.6 2.0 ± 0.6* 1.9 ± 0.5*
.3 ± 25.6 71.6 ± 24.2 53.0 ± 18.6
.6 ± 12.9 29.2 ± 6.7 28.8 ± 12.0
ts without diabetes fed a high-fat diet; DM ¼ rats with diabetes fed a
ansii; IL-6 ¼ interleukin-6; PAI-1 ¼ plasminogen activator inhibitor-1;
-fat diet with thiazolidinedione in the diet.
¼ (fasting plasma glucose concentration (mmol/L)  fasting plasma
Table 4 e Plasma, liver, and fecal lipid concentrations in rats with diabetes fed different experimental diets for 11 weeks.
Con DM TZD GA
Plasma
Total cholesterol (mg/dL) 117.1 ± 44.1 131.3 ± 15.4 87.1 ± 33.4* 96.1 ± 29.9*
Triglyceride (mg/dL) 44.3 ± 10.4* 72.1 ± 23.6 35.0 ± 12.4* 34.5 ± 10.4*
HDL-C (mg/dL) 33.5 ± 7.0 37.3 ± 6.0 28.2 ± 10.4 31.0 ± 14.2
LDL-C þ VLDL-C (mg/dL) 83.6 ± 41.8 94.0 ± 17.0 58.8 ± 23.6* 65.1 ± 16.5*
TC/HDL-C 3.5 ± 1.2 3.6 ± 0.8 3.1 ± 0.3 3.2 ± 0.4
HDL-C/(LDL-C þ VLDL-C) 0.46 ± 0.15 0.41 ± 0.12 0.49 ± 0.09 0.47 ± 0.10
Liver
Total cholesterol (g/Liver) 4.9 ± 1.9* 9.3 ± 1.5 6.0 ± 2.4* 5.8 ± 2.4*
Triglyceride (g/Liver) 5.4 ± 2.9* 13.4 ± 3.6 5.8 ± 2.1* 5.0 ± 2.6*
Feces
Total cholesterol (mg/g) 9.4 ± 1.6 8.9 ± 1.3 10.0 ± 2.6 11.5 ± 2.1*
Triglyceride (mg/g) 3.1 ± 0.7 3.0 ± 0.7 4.7 ± 2.8 6.9 ± 3.6*
Data are presented as mean ± SD values (n ¼ 7e8).
*p < 0.05 compared with the DM group.
Con ¼ rats without diabetes fed a high-fat diet; DM ¼ rats with diabetes fed a high-fat diet; GA ¼ rats with diabetes fed a high-fat diet and
Gelidium amansii; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; TC ¼ total cholesterol; TZD ¼ rats
with diabetes fed a high-fat diet with thiazolidinedione in the diet; VLDL-C ¼ very-low-density lipoprotein cholesterol.
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group than in the control group. In both the TZD and GA
groups, however, liver total cholesterol and triglyceride levels
were significantly lower (p < 0.05) than in the DM group. In
addition, daily fecal excretions of total cholesterol and tri-
glycerides were significantly higher (p < 0.05) in the GA group
than in the DM group.
3.5. Lipolysis rate, triglyceride content, and LPL activity
in adipose tissues
The triglyceride content of paraepididymal and perirenal fat
pads tended to be higher in the DM group than in the control
group, however, this difference was not significant (p > 0.05;
Fig. 1). In the GA group, however, the triglyceride content of
the per grams perirenal adipose pads was significantly lower
(p < 0.05) than in the DM group (Fig. 1A); moreover, the total
triglyceride amount of paraepididymal and perirenal adipose
pads were significantly lower (p < 0.05; Fig. 1B) than in the DM
group. In addition, the lipolysis rates of the paraepididymalFig. 1 e Changes in triglyceride content of (A) per grams and (B)
diabetes fed different experimental diets for 11 weeks. Data are m
a high-fat diet; DM ¼ rats with diabetes fed a high-fat diet; GA ¼
SD¼ standard deviation; TZD¼ rats with diabetes fed a high-fa
with the DM group.and perirenal fat pads were markedly induced (p < 0.05) in the
GA and TZD groups compared with the DM group (Fig. 2).
There was no significant difference in LPL activities of para-
epididymal and perirenal fat pads between the GA group and
control group in rats with diabetes (p > 0.05; Fig. 3).4. Discussion
Type 2 diabetes is always combined with hyperglycemia and
hyperlipidemia [29]. In this study, we found that feeding a
high-fat diet to rats with streptozotocin-nicotinamide-
induced diabetes resulted in higher plasma glucose and in-
sulin resistance, the typical symptoms of type 2 diabetes. Our
results also showed that GA feeding may reduce plasma
glucose, lipids, and adipocytokine levels and prevent adipose
tissue accumulation through induced lipolysis and lipoprotein
lipase activity in rats with diabetes.
In this study, the high plasma glucose level in rats with
diabetes could be reduced (13%) by GA feeding for 11 weeks.per total paraepididymal and perirenal fat pads in rats with
ean ± SD values (n¼ 7e8). Con¼ rats without diabetes fed
rats with diabetes fed a high-fat diet and Gelidium amansii;
t diet with thiazolidinedione in the diet. *p < 0.05 compared
Fig. 2 e Changes in the lipolysis rate of paraepididymal
and perirenal fat pads in rats with diabetes fed the
different experimental diets for 11 weeks. Data are
mean ± SD values (n ¼ 7e8). Con ¼ rats without diabetes
fed a high-fat diet; DM ¼ rats with diabetes fed a high-fat
diet; GA ¼ rats with diabetes fed a high-fat diet and
Gelidium amansii; SD¼ standard deviation; TZD¼ rats with
diabetes fed a high-fat diet with thiazolidinedione in the
diet. *p < 0.05 compared with the DM group.
Fig. 3 e Changes in the lipoprotein lipase activity of
paraepididymal and perirenal fat pads in rats with
diabetes fed the different experimental diets for 11 weeks.
Data are mean ± SD values (n ¼ 7e8). Con ¼ rats without
diabetes fed a high-fat diet; DM ¼ rats with diabetes fed a
high-fat diet; GA ¼ rats with diabetes fed a high-fat diet
and Gelidium amansii; SD ¼ standard deviation; TZD ¼ rats
with diabetes fed a high-fat diet with thiazolidinedione in
the diet. *p < 0.05 compared with the DM group.
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reduced plasma glucose levels, this effect appeared to be su-
perior to the change in animals treated with TZD, a drug that
can activate peroxisome proliferator activated receptor g and
promote insulin sensitivity [30]. It has been reported that
some phytochemicals such as rutin (23,200 mg/g) and hesper-
idin (88,000 mg/g) are both abundant flavonoids in the raw
material of GA [31]. Moreover, rutin and hesperidin both have
antiobesity [32,33] and hypoglycemic activities [34,35]. How-
ever, the dry material of GA is processed from the raw mate-
rial of GA by sunlight exposure that may result in the decay of
these phytochemicals. Indeed, we found relatively low con-
tents of rutin (4.52 mg/g) and hesperidin (1.65 mg/g) in the dry
material of GA. Therefore, in this study, rutin and hesperidin
were excluded as the active components of GA on improving
glucose metabolism and lowering adipose tissue. GA,however, contains abundant (45.9%) water-soluble fiber. Sci-
entists have reported that water-soluble fiber in the gastro-
intestinal tract can delay carbohydrate absorption and
suppress the increase in postprandial blood glucose levels
[36,37]. Long-term intake of water-soluble fiber helps to
improve the hyperinsulinemia of type 2 diabetes [38]. There-
fore, we suggest that the reduction in plasma glucose with GA
feeding may be partially related to its high water-soluble fiber
content, which might delay carbohydrate digestion and lower
the increase in blood glucose after a meal.
It is interesting to note that rats fed a diet with GA signif-
icantly reduced plasma leptin level and lowered triglyceride
content in adipose tissues. This observation, however, was
surprisingly and notably not found in the TZD group.
Although both TZD and GA improved insulin sensitivity and
reduced glucose levels in rats with diabetes, GA displayed a
unique property on reducing triglyceride accumulation in
adipose tissue. Adipose tissue is an important endocrine
organ that secretes multiple adipocytokines affecting energy
metabolism and insulin sensitivity [39]. Hypertrophic adipo-
cytes may increase plasma leptin, TNF-a, and IL-6 concen-
trations, but decrease the plasma adiponectin level. In the
current study, GA feeding significantly reduced adipose tissue
weight (paraepididymal and perirenal). Plasma TNF-a and IL-6
concentrations were increased and adiponectin was
decreased in rats with diabetes. Consistent with previous re-
sults, our results showed that TZD, an insulin receptor
sensitizer, could significantly improve adiponectin levels in
type 2 diabetes [40]. GA feeding reduced adipose weight and
reversed the increase in plasma adipocytokine levels in rats
with diabetes. These results indicate that GA may regulate
plasma adipocytokines by lowering adipose tissue weight in
rats with diabetes.
PAI-1 secreted fromadipocytes is oneof thekey inhibitorsof
fibrinolysis and is associated with the development of athero-
sclerosis in patientswith diabetes [41,42]. PAI-1 concentrations
are particularly high in obesity and type 2 diabetes [43]. Our
results showed that GA lowered adipose tissue weight, TNF-a,
and PAI-1 concentrations. Because TNF-a can stimulate PAI-1
secretion [44,45], lower TNF-a levels may lead to decreased
PAI-1 secretion. It is possible that the decreased PAI-1 levels
after GA treatment may have resulted from lower adipose tis-
sue and TNF-a levels. Our results further suggested that lower
PAI-1 concentration by feeding with GAmay reduce the risk of
thrombosis and atherosclerosis in rats with diabetes.
Hormone-sensitive lipase (HSL) is an enzyme that pro-
motes fatty tissue decomposition [46] and conducts lipolysis
from triacylglycerol to monoacylglycerol and free fatty acids
[47]. Watt et al. [48] showed that HSL activity is lower in type 2
diabetes, which may be a mechanism by which obesity is
accelerated in diabetes. Similar to the actions observed in the
TZD group, our results showed that triglyceride contents were
lower and the rate of lipolysis was higher in adipose tissue
(paraepididymal and perirenal) from rats in the GA group (GA
vs. DM; Figs. 1 and 2). Therefore, GA feeding could induce the
rate of lipolysis and thus lower triglyceride content in adipose
tissue, thereby reducing the adipose tissue weight in rats with
diabetes.
Patients with type 2 diabetes usually show symptoms of
hyperlipidemia and fatty liver in the clinic [49]. In the current
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 3 ( 2 0 1 5 ) 7 5 8e7 6 5764study, hyperglycemia, hyperlipidemia, and fatty liver were
found in the rats with diabetes. In addition to lowering plasma
glucose levels, GA feeding also reduced total cholesterol and
triglyceride concentrations in the plasma and liver of ratswith
diabetes. This result is consistent with the finding that water-
soluble fiber supplementation can reduce plasma and liver
lipids in rats [50,51] and humans [16,38] with diabetes. More-
over, it has been shown that the increase in fecal lipid
excretion by some water-soluble fiber may be the reason for
the lower plasma and liver lipids [52]. It is interesting to note
that GA increased fecal total cholesterol and triglyceride
excretion. It is therefore suggested that the reduced plasma
and liver lipids after GA treatment may have been due to the
increase in fecal lipid excretion.
In conclusion, our results show that GA may improve
plasma glucose and liquids and increase lipolysis activity,
resulting in the reduction of adipose tissue, thereby reducing
TNF-a, IL-6, and PAI-1 and lowering the risk of chronic
inflammationandcardiovascular disease in ratswithdiabetes.Conflicts of interest
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